Stereotaxis Robotic Technology Now Referenced In Over 400 Scientific Publications
June 02 2020 - 9:00AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced it has reached a significant milestone of over 400
scientific publications now documenting the clinical benefits of
Stereotaxis robotic technology. A complete, searchable database of
all publications is available online at
www.RoboticEP.com/Clinical-Data.
“The clinical benefits of Robotic Magnetic
Navigation have been extensively validated in high-quality clinical
literature and in the real-world treatment of over
one-hundred-thousand arrhythmia patients,” said David Fischel,
Chairman and CEO. “We are proud of the depth and breadth of
clinical data demonstrating the benefits of robotics to patients
and healthcare providers. We congratulate and thank the physicians
globally who have contributed to this robust body of clinical
evidence.”
The most recent publication, published in
Clinical Cardiology by Dr. Jin Qi and colleagues from Ruijin
Hospital in Shanghai, describes clinical outcomes of 1,003
consecutive robotic cardiac ablation procedures performed between
2010 and 2019. It is among the largest single-center publications
documenting efficacy, safety, speed and learning curve of Robotic
Magnetic Navigation. The 1,003 patients suffered from a broad range
of arrhythmias with 55% of the patients being treated for Atrial
Fibrillation, 29% for Ventricular Tachycardia or Premature
Ventricular Contraction, 11% for Supraventricular Tachycardia, and
5% for Atrial Tachycardia or Atrial Flutter. Key findings
include:
- Improved Safety – Across 1,003 robotic procedures the total
complication rate was 0.5%. The publication compared this rate to a
larger epidemiological study of traditional cardiac ablation
showing a 10-fold higher complication rate of 5.46%.
- Efficacy – The study reported 99.0% successful pulmonary vein
isolation in Atrial Fibrillation procedures and 90.3% acute
procedure success in Ventricular Tachycardia and Premature
Ventricular Contraction procedures.
- X-Ray Exposure – The mean total x-ray time of 5.3 minutes
across all arrhythmia types was described by the authors as
“remarkably low.”
- Efficiency & Learning Curve – The publication reported a
mean procedure time across all arrhythmia types of 126 minutes.
There was a significant improvement in efficiency with increased
experience.
Dr. Jin commented, “At our hospital, robotic
guided ablation for cardiac arrhythmias clearly and consistently
provides improved patient care and an excellent operator
experience. We look forward to more progress in the future as
robotic technology creates a foundation for artificial intelligence
and remote treatment in interventional electrophysiology.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024